ABSTRACT
Background Impella Left ventricular assist device (LVAD) is used for hemodynamic support during high risk coronary interventions and in patients with cardiogenic shock. Data on percutaneous Impella ventricular assist device related 30-day readmissions are not well studied
Methods The Healthcare Cost and Utilization Project National Readmission Database was used to identify index hospitalization with Impella placement in patients ≥18 years old. Multivariate logistic regression analyses were used to examine factors associated with risk of 30-day readmissions. Results
We evaluated 5,941 hospitalized patients who survived to discharge after index hospitalization from January through November 2018 and analyzed readmissions over 30 days after discharge. A total of 1,418 patients (24%) were readmitted within 30 days, the most common reasons for readmission included acute myocardial infarction (27%) and heart failure (15%).
Conclusions 30-day readmissions were associated with a significant increase in healthcare costs. The majority of readmissions were secondary toacute myocardial infarction and heart failure. Ongoing efforts are required to recognize and reduce potentially preventable readmissions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from: https://www.hcup-us.ahrq.gov/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
